Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 11/20 | 0.56 |
| ▸ | CDK2 | P24941 | 6/20 | 0.48 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.44 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13288939 | 0.95 | GSK3B (0.56) | GSK3BCDK2CHEK1CCNE1NAMPT | |
| SCHEMBL13288938 | 0.92 | GSK3B (0.55) | GSK3BCDK2CHEK1CCNE1LMNA | |
| SCHEMBL14607248 | 0.92 | GSK3B (0.53) | GSK3BCDK2CHEK1CCNE1LMNA | |
| SCHEMBL13289108 | 0.92 | GSK3B (0.56) | GSK3BCDK2CHEK1CCNE1NAMPT | |
| SCHEMBL13289368 | 0.92 | GSK3B (0.56) | GSK3BCDK2CHEK1CCNE1 | |
| SCHEMBL14545240 | 0.92 | GSK3B (0.56) | GSK3BCDK2CHEK1CCNE1NAMPT | |
| SCHEMBL13289103 | 0.92 | GSK3B (0.56) | GSK3BCDK2CHEK1CCNE1LMNA | |
| SCHEMBL13289405 | 0.91 | GSK3B (0.57) | GSK3BCDK2CHEK1CCNE1NAMPT | |
| SCHEMBL14545840 | 0.91 | GSK3B (0.53) | GSK3BCDK2CHEK1CCNE1LMNA | |
| SCHEMBL13289013 | 0.91 | GSK3B (0.55) | GSK3BCDK2CHEK1CCNE1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2194058-A1 | Pyrazolopyrimidines suitable for the treatment of cancer diseases | SCHERING CORPORATION (US) | 2010-06-09 | — | — | EP | disclosed |